Mechanisms of β-cell death in type 2 diabetes

Diabetes

Volumn 54, Issue SUPPL. 2, 2005, Pages

  Donath, Marc Y ^a   Ehses, Jan A ^a   Maedler, Kathrin ^a   Schumann, Desiree M ^a   Ellingsgaard, Helga ^a   Eppler, Elisabeth ^b   Reinecke, Manfred ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIDIABETIC AGENT; CYTOKINE; DIAZOXIDE; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1BETA; LEPTIN; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ADAPTATION; APOPTOSIS; AUTOIMMUNITY; CELL DEATH; CELL FUNCTION; CELL PROLIFERATION; CELL SECRETION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CYTOTOXICITY; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; HUMAN; INFLAMMATION; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRESS; TURNOVER TIME;

ANIMALS; CELL DEATH; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; INSULIN-SECRETING CELLS; LEPTIN; RISK FACTORS;

EID: 33644747390     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.54.suppl_2.S108     Document Type: Review

References (84)

1. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003
2. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S: Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 45:85-96, 2002
3. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, Yoo SJ, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim HS, Lee IK, Bonner-Weir S: Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300-2308, 2003
4. Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK: Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 23:1755-1760, 2000
5. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC: Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47:1661-1667, 2004
6. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T: Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 81:455-470, 2003
7. Donath MY, Halban PA: Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47:581-589, 2004
8. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 28 (Suppl. 1):S37-S42, 2005
9. Chick WL, Like AA: Studies in the diabetic mutant mouse. 3. Physiological factors associated with alterations in beta cell proliferation. Diabetologia 6:243-251, 1970
10. Donath MY, Gross DJ, Cerasi E, Kaiser N: Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738-744, 1999
11. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A, Kaiser N, Donath MY: Glucose induces beta-cell apoptosis via upregulation of the Fas-receptor in human islets. Diabetes 50:1683-1690, 2001
12. 2+ concentration. J Biol Chem 273:33501-33507, 1998
13. Hoorens A, Van de Casteele M, Kloppel G, Pipeleers D: Glucose promotes survival of rat pancreatic beta cells by activating synthesis of proteins which suppress a constitutive apoptotic program. J Clin Invest 98:1568-1574, 1996
14. Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, Usellini L, Nano R, Bonini P, Bertuzzi F, Marlier LN, Davalli AM, Carandente O, Pontiroli AE, Melino G, Marchetti P, Lauro R, Sesti G, Folli F: High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 50:1290-1301, 2001
15. Weir GC, Bonner-Weir S: Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53 (Suppl. 3):S16-S21, 2004
16. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276, 1999
17. Maedler K, Fontana A, Ris F, Sergeev P, Toso C, Oberholzer J, Lehmann R, Bachmann F, Tasinato A, Spinas GA, Halban PA, Donath MY: FLIP switches Fas-mediated glucose signaling in human pancreatic β cells from apoptosis to cell replication. Proc Natl Acad Sci U S A 99:8236-8241, 2002
18. Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY: Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 52:726-733, 2003
19. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T, Dayer JM, Reinecke M, Halban PA, Donath MY: Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 101:8138-8143, 2004
20. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY: Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851-860, 2002
21. Bonner-Weir S: Islet growth and development in the adult. J Mol Endocrinol 24:297-302, 2000
22. Laybutt DR, Glandt M, Xu G, Ahn YB, Trivedi N, Bonner-Weir S, Weir GC: Critical reduction in beta-cell mass results in two distinct outcomes over time: adaptation with impaired glucose tolerance or decompensated diabetes. J Biol Chem 278:2997-3005, 2003
23. Mine T, Miura K, Okutsu T, Mitsui A, Kitahara Y: Gene expression profile in the pancreatic islets of Goto-Kakizaki (GK) rats with repeated postprandial hyperglycemia. Diabetes 53 (Suppl. 2):2475A, 2004
24. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC: Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 53:1509-1516, 2004
25. Mellado-Gil JM, Aguilar-Diosdado M: High glucose potentiates cytokine- and streptozotocin-induced apoptosis of rat islet cells: effect on apoptosis-related genes. J Endocrinol 183:155-162, 2004
26. Weir GC, Clore ET, Zmachinski CJ, Bonner-Weir S: Islet secretion in a new experimental model for non-insulin-dependent diabetes. Diabetes 30:590-595, 1981
27. Unger RH, Grundy S: Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 28:119-121, 1985
28. Robertson RP: Type II diabetes, glucose "non-sense," and islet desensitization. Diabetes 38:1501-1505, 1989
29. Leahy JL, Cooper HE, Deal DA, Weir GC: Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion: a study in normal rats using chronic in vivo glucose infusions. J Clin Invest 77:908-915, 1986
30. Leahy JL, Weir GC: Evolution of abnormal insulin secretory responses during 48-h in vivo hyperglycemia. Diabetes 37:217-222, 1988
31. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY: Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes 50:69-76, 2001
32. Dyntar D, Eppenberger-Eberhardt M, Maedler K, Pruschy M, Eppenberger HM, Spinas GA, Donath MY: Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 50:2105-2113, 2001
33. Cnop M, Hannaert JC, Grupping AY, Pipeleers DG: Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 143:3449-3453, 2002
34. Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, Azhar S, Bideau M, Capponi A, Nicod P, Haefliger JA, Waeber G: Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 278:18368-18375, 2003
35. El-Assaad W, Buteau J, Peyot ML, Nolan C, Roduit R, Hardy S, Joly E, Dbaibo G, Rosenberg L, Prentki M: Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 144:4154-4163, 2003
36. Poitout V, Robertson RP: Minireview: secondary beta-cell failure in type 2 diabetes: a convergence of glucotoxicity and lipotoxicity. Endocrinology 143:339-342, 2002
37. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ, Gualillo O: Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 579:295-301, 2005
38. Matarese G, Sanna V, Lechler RI, Sarvetnick N, Fontana S, Zappacosta S, La Cava A: Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes 51:1356-1361, 2002
39. Barbier M, Cherbut C, Aube AC, Blottiere HM, Galmiche JP: Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut 43:783-790, 1998
40. Sanna V, Di Giacomo A, La Cava A, Lechler RI, Fontana S, Zappacosta S, Matarese G: Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 111:241-250, 2003
41. Kieffer TJ, Habener JF: The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 278:E1-E14, 2000
42. Roduit R, Thorens B: Inhibition of glucose-induced insulin secretion by long-term preexposure of pancreatic islets to leptin. FEBS Lett 415:179-182, 1997
43. Hennige AM, Burks DJ, Ozcan U, Kulkarni RN, Ye J, Park S, Schubert M, Fisher TL, Dow MA, Leshan R, Zakaria M, Mossa-Basha M, White MF: Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 112:1521-1532, 2003
44. Rhodes CJ: Type 2 diabetes: a matter of beta-cell life and death? Science 307:380-384, 2005
45. Kwon G, Corbett JA, Rodi CP, Sullivan P, McDaniel ML: Interleukin-1 beta-induced nitric oxide synthase expression by rat pancreatic beta-cells: evidence for the involvement of nuclear factor kappa B in the signaling mechanism. Endocrinology 136:4790-4795, 1995
46. Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA: Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 89:5059-5066, 2004
47. Giannoukakis N, Rudert WA, Trucco M, Robbins PD: Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. J Biol Chem 275:36509-36513, 2000
48. Shoelson SE, Lee J, Yuan M: Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 27 (Suppl. 3):S49-S52, 2003
49. Shoelson S: Invited comment on W. Ebstein: on the therapy of diabetes mellitus, in particular on the application of sodium salicylate. J Mol Med 80:618-619, 2002
50. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183-190, 2005
51. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11:191-198, 2005
52. Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J: Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 47:249-258, 2004
53. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599-622, 2002
54. Norlin S, Ahlgren U, Edlund H: Nuclear factor-κB activity in β-cells is required for glucose-stimulated insulin secretion. Diabetes 54:125-132, 2005
55. Izumi T, Yokota-Hashimoto H, Zhao S, Wang J, Halban PA, Takeuchi T: Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes 52:409-416, 2003
56. Harding HP, Ron D: Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 51 (Suppl. 3):S455-S461, 2002
57. Araki E, Oyadomari S, Mori M: Endoplasmic reticulum stress and diabetes mellitus. Intern Med 42:7-14, 2003
58. Weber SM, Chambers KT, Bensch KG, Scarim AL, Corbett JA: PPARgamma ligands induce ER stress in pancreatic beta-cells: ER stress activation results in attenuation of cytokine signaling. Am J Physiol Endocrinol Metab 287:E1171-E1177, 2004
59. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisligil GS: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457-461, 2004
60. Lowell BB, Shulman GI: Mitochondrial dysfunction and type 2 diabetes. Science 307:384-387, 2005
61. Brissova M, Shiota M, Nicholson WE, Gannon M, Knobel SM, Piston DW, Wright CV, Powers AC: Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem 277:11225-11232, 2002
62. Gauthier BR, Brun T, Sarret EJ, Ishihara H, Schaad O, Descombes P, Wollheim CB: Oligonucleotide microarray analysis reveals PDX1 as an essential regulator of mitochondrial metabolism in rat islets. J Biol Chem 279:31121-31130, 2004
63. Lameloise N, Muzzin P, Prentki M, Assimacopoulos-Jeannet F: Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes 50:803-809, 2001
64. Kulkarni RN, Jhala US, Winnay JN, Krajewski S, Montminy M, Kahn CR: PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J Clin Invest 114:828-836, 2004
65. Johnson JD, Ahmed NT, Luciani DS, Han Z, Tran H, Fujita J, Misler S, Edlund H, Polonsky KS: Increased islet apoptosis in Pdx1+/- mice. J Clin Invest 111:1147-1160, 2003
66. Robertson RP, Harmon J, Tran PO, Poitout V: Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53 (Suppl. 1):S119-S124, 2004
67. Green K, Brand MD, Murphy MP: Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53 (Suppl. 1):S110-S118, 2004
68. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52:1-8, 2003
69. Iwakura T, Fujimoto S, Kagimoto S, Inada A, Kubota A, Someya Y, Ihara Y, Yamada Y, Seino Y: Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun 271:422-428, 2000
70. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY: Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501-506, 2005
71. Del Guerra S, Marselli L, Lupi R, Boggi U, Mosca F, Benzi L, Del Prato S, Marchetti P: Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications 19:60-64, 2005
72. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill V: Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26:2231-2237, 2003
73. U.K. Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
74. Maedler K, Storling J, Sturis J, Zuellig RA, Spinas GA, Arkhammar PO, Mandrup-Poulsen T, Donath MY: Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 53:1706-1713, 2004
75. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC: Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab 89:795-805, 2004
76. Greenwood RH, Mahler RF, Hales CN: Improvement in insulin secretion in diabetes after diazoxide. Lancet 1:444-447, 1976
77. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA: Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45:1427-1430, 1996
78. Guldstrand M, Grill V, Bjorklund A, Lins PE, Adamson U: Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabete Metab 28:448-456, 2002
79. Drucker DJ: Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144:5145-5148, 2003
80. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478, 2003
81. Mathis D, Vence L, Benoist C: Beta-cell death during progression to diabetes. Nature 414:792-798, 2001
82. Bellone M, Iezzi G, Rovere P, Galati G, Ronchetti A, Protti MP, Davoust J, Rugarli C, Manfredi AA: Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 159:5391-5399, 1997
83. Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, Finegood DT: Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? Diabetes 49:1-7, 2000
84. Hull RL, Westermark GT, Westermark P, Kahn SE: Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89:3629-3643, 2004